These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 28151736

  • 21. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?
    Gilissen LP, Derijks LJ, Driessen A, Bos LP, Hooymans PM, Stockbrügger RW, Engels LG.
    Dig Liver Dis; 2007 Feb; 39(2):156-9. PubMed ID: 17188950
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
    Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin TH.
    Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
    [Abstract] [Full Text] [Related]

  • 24. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
    Wall GC, Muktar H, Effken C, Mahajan PB.
    Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117
    [Abstract] [Full Text] [Related]

  • 25. IBD: Switching metabolism-can two drugs be better than one?
    Sparrow MP.
    Nat Rev Gastroenterol Hepatol; 2010 Aug; 7(8):420-2. PubMed ID: 20683489
    [No Abstract] [Full Text] [Related]

  • 26. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.
    Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, Tran T, Martin P, Vierling JM, Targan SR.
    Am J Surg Pathol; 2004 Sep; 28(9):1204-11. PubMed ID: 15316320
    [Abstract] [Full Text] [Related]

  • 27. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients.
    de Boer NK, Zondervan PE, Gilissen LP, den Hartog G, Westerveld BD, Derijks LJ, Bloemena E, Engels LG, van Bodegraven AA, Mulder CJ.
    Dig Liver Dis; 2008 Feb; 40(2):108-13. PubMed ID: 18083079
    [Abstract] [Full Text] [Related]

  • 28. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
    Gilissen LP, Bierau J, Derijks LJ, Bos LP, Hooymans PM, van Gennip A, Stockbrügger RW, Engels LG.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):605-11. PubMed ID: 16181300
    [Abstract] [Full Text] [Related]

  • 29. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.
    Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W.
    Wien Klin Wochenschr; 2007 Oct 01; 119(17-18):519-26. PubMed ID: 17943403
    [Abstract] [Full Text] [Related]

  • 30. Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.
    Serpico MR, Maltz R, Crandall W, Bricker J, Dotson JL, Kim SC, Boyle B.
    J Pediatr Gastroenterol Nutr; 2018 Sep 01; 67(3):341-345. PubMed ID: 29601433
    [Abstract] [Full Text] [Related]

  • 31. Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study.
    Pavlidis P, Stamoulos P, Abdulrehman A, Kerr P, Bull C, Duley J, Ansari A.
    Inflamm Bowel Dis; 2016 Jul 01; 22(7):1639-46. PubMed ID: 27271488
    [Abstract] [Full Text] [Related]

  • 32. Safety and Efficacy of Split-Dose Thiopurine vs Low-Dose Thiopurine-Allopurinol Cotherapy in Pediatric Inflammatory Bowel Disease.
    Cococcioni L, Pensabene L, Puoti MG, El-Kouly S, Chadokufa S, Buckingham R, Gaynor E, Saliakellis E, Kiparissi F, Borrelli O.
    Clin Transl Gastroenterol; 2023 Mar 01; 14(3):e00544. PubMed ID: 36729814
    [Abstract] [Full Text] [Related]

  • 33. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).
    Friedman AB, Brown SJ, Bampton P, Barclay ML, Chung A, Macrae FA, McKenzie J, Reynolds J, Gibson PR, Hanauer SB, Sparrow MP.
    Aliment Pharmacol Ther; 2018 Apr 01; 47(8):1092-1102. PubMed ID: 29468701
    [Abstract] [Full Text] [Related]

  • 34. Is there a role for thioguanine therapy in IBD in 2017 and beyond?
    Taylor KM, Ward MG, Blaker PA, Sparrow MP.
    Expert Rev Gastroenterol Hepatol; 2017 May 01; 11(5):473-486. PubMed ID: 28276819
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.
    Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP.
    J Crohns Colitis; 2010 Nov 01; 4(5):546-52. PubMed ID: 21122558
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature.
    Witte TN, Ginsberg AL.
    Can J Gastroenterol; 2008 Feb 01; 22(2):181-5. PubMed ID: 18299738
    [Abstract] [Full Text] [Related]

  • 39. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis.
    de Boer YS, van Gerven NM, de Boer NK, Mulder CJ, Bouma G, van Nieuwkerk CM.
    Aliment Pharmacol Ther; 2013 Mar 01; 37(6):640-6. PubMed ID: 23347359
    [Abstract] [Full Text] [Related]

  • 40. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.
    Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J.
    Aliment Pharmacol Ther; 2008 Sep 15; 28(6):734-41. PubMed ID: 19145729
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.